Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)
Public ClinicalTrials.gov record NCT04895722. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Multi Arm, Study to Evaluate MK-1308A (Co-formulated Quavonlimab (MK-1308)/Pembrolizumab) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer: (MK-1308A-008)
Study identification
- NCT ID
- NCT04895722
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 302 participants
Conditions and interventions
Conditions
Interventions
- MK-4830 Biological
- Pembrolizumab Biological
- Pembrolizumab/Favezelimab Biological
- Pembrolizumab/Quavonlimab Biological
- Pembrolizumab/Vibostolimab Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 24, 2021
- Primary completion
- May 20, 2025
- Completion
- Aug 12, 2026
- Last update posted
- Mar 29, 2026
2021 – 2026
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mid Florida Cancer Center ( Site 1519) | Orange City | Florida | 32763 | — |
| University Cancer & Blood Center, LLC ( Site 1521) | Athens | Georgia | 30607 | — |
| University of Chicago Medical Center-Medicine - Section of Hematology/Oncology - Gastrointestinal P | Chicago | Illinois | 60637 | — |
| Icahn School of Medicine at Mount Sinai ( Site 1528) | New York | New York | 10029 | — |
| Hematology Oncology Associates of Rockland ( Site 1525) | Nyack | New York | 10960 | — |
| UPMC Hillman Cancer Center ( Site 1516) | Pittsburgh | Pennsylvania | 15232 | — |
| The West Clinic, PLLC dba West Cancer Center ( Site 1576) | Germantown | Tennessee | 38138 | — |
| Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 1509) | Nashville | Tennessee | 37232 | — |
| UT Southwestern Medical Center ( Site 1551) | Dallas | Texas | 75390 | — |
| Baylor Scott & White Medical Center - Temple-Division of Hematology/Oncology ( Site 1549) | Temple | Texas | 76508 | — |
| Northwest Medical Specialties, PLLC ( Site 1546) | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 98 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04895722, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 29, 2026 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04895722 live on ClinicalTrials.gov.